IDRI (Infectious Disease Research Institute) is a nonprofit, global health organization with a comprehensive approach to combatting infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company. Our goal: to create new diagnostics, drugs and vaccines.

Founded in 1993 by Dr. Steven Reed, IDRI has 125 employees headquartered in Seattle with nearly 100 partners around the world. IDRI has had notable success providing solutions that have significantly reduced the global burden of disease, including diagnostic tests currently on the market. Our advanced product pipeline has the potential to save millions of lives.

WHAT DIFFERENTIATES IDRI?

APPLIED FOCUS.
Unlike most not for profit research institutes, IDRI has fully integrated product development capabilities, ranging from early stage discovery to clinical trials, including GMP manufacturing. Because of this, IDRI is often the collaborator of choice for other research groups with early stage programs.

DEMONSTRATED DEVELOPMENT SUCCESS.
IDRI has diagnostic products on the market. IDRI’s diagnostic for Chagas disease antigens is currently commercialized by Abbott and several smaller companies, and is being used to help screen the U.S. blood supply for Chagas parasite contamination. IDRI has also developed diagnostics for leishmaniasis, currently distributed to the market by multiple licensing partners on four continents. Our most recent success is a diagnostic for leprosy, recently licensed for use in Brazil. We also have developed vaccines for TB and leishmaniasis, currently in clinical trials, and are in the discovery/development phase for new drugs to combat TB.

COMPREHENSIVE SOLUTIONS TO DISEASE PROBLEMS.
IDRI has the internal scientific capability to approach seemingly intractable diseases with comprehensive solutions: diagnostics for early detection, allowing early drug therapy, coupled with vaccine development to ultimately eradicate disease. For those diseases addressed by IDRI, there is no other institution dedicated to global health with similar comprehensive capabilities.

UNIQUE POSITION RELATED TO ADJUVANT DEVELOPMENT FOR NEGLECTED DISEASES.
Adjuvants are immune stimulators that can be combined with antigens to create vaccine products that have greater protection and increased activity at lower and fewer doses. IDRI’s proprietary collection of adjuvant molecules, coupled with its expertise in adjuvant and adjuvant-antigen formulation, have resulted in a world leadership position in the adjuvant area. IDRI’s adjuvant portfolio has broad uses for infectious diseases within IDRI’s current areas of expertise (tuberculosis, leishmaniasis, malaria, influenza, and leprosy) as well as for the neglected diseases of interest pursued by our collaborative organizations.
IDRI employs over 125 full-time personnel in its efforts, including many with advanced degrees. The management team is made up of experienced, highly regarded personnel from the biotechnology, nonprofit and research communities.

**Management Team Personnel**

- **Chris Antony**
  - VP, Operations

- **Anna Marie Beckmann, PhD**
  - VP, Development & Regulatory

- **Darrick Carter, PhD**
  - VP, Adjuvant Technology

- **Rhea Coler, PhD**
  - VP, Preclinical Biology

- **Erik Iverson, JD, LLM**
  - President, Business & Operations

- **Rob Lin, PhD, CFA**
  - VP, Finance

- **Tanya Parish, PhD**
  - VP, Drug Discovery

- **Steven G. Reed, PhD**
  - Founder, President & Chief Scientific Officer

- **Thomas Vedvick, PhD**
  - VP, Formulation & Process Development

**Board of Directors**

- **Bruce Carter, PhD**
  - Former President of ZymoGenetics

- **Gail Cassell, PhD**
  - Visiting Professor, Harvard

- **Michel De Wilde, PhD**
  - Consultant

- **Christopher Hentschel, PhD**
  - Partner

- **Life Science Ventures**
  - Former CEO of Medicines for Malaria Venture

- **Erik Iverson, JD, LLM**
  - President, Business & Operations, IDRI

- **David Perry, MBA**
  - President/CEO, Symbiota

- **Franklyn G. Prendergast, MD, PhD**
  - Edmond & Marion Guggenheim Professor of Biochemistry & Molecular Biology

- **Massimo Radaelli, PhD**
  - President/Founder

- **Steven G. Reed, PhD**
  - Founder/President/CSO

- **Paul G Allen Family Foundation**
  - Glaxo Smith Kline

- **American Leprosy Missions**
  - BARDA (US HHS) / DARPA (US DOD)

- **Wellcome Trust**

**Select Funders**

- **Bill & Melinda Gates Foundation**
- **Billboard Health Organization**
- **National Institutes of Health**
- **The MJ Murdock Charitable Trust**
- **Eli Lilly & Company**

We target diseases that kill more than six million people each year.

Although these diseases have different symptoms, global footprints, and challenges, we have a singular goal for each program: developing diagnostics, vaccines, and drugs that save lives and improve health outcomes.

**2014 Research Budget:** ~$20 Million